Clinical Trial Update: A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a terminated Phase 1/2 study evaluating sunitinib plus exemestane in ER-positive and/or PgR-positive breast cancer; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2010-08-30